Actively Recruiting
Evaluating OssiMend Bioactive Moldable Device in Adults Undergoing Lumbar Spine Fusion for Degenerative Disc Disease
Led by Collagen Matrix · Updated on 2025-10-16
120
Participants Needed
4
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the success rate of lumbar fusion surgery in adults with degenerative disc disease DDD using a device called OssiMend Bioactive Moldable as the bone graft material. The study aims to measure fusion success at 12 months by examining X-rays and checking for serious side effects related to the device. They will also assess clinical outcomes such as pain and quality of life over one year, with possible follow-up up to two years. Participants will undergo instrumented lumbar arthrodesis, where OssiMend Bioactive Moldable is used during the spine fusion procedure. This study observes patients receiving this treatment without comparing to other treatments or placebo. The main study period focuses on the 12 months following surgery, with monitoring of fusion success and safety. Secondary assessments include pain scales and questionnaires about back pain and general health. During the study, participants will have evaluations including radiographic imaging to confirm bone fusion and questionnaires to measure pain levels and physical function. Researchers will monitor for any serious adverse events related to the device. Participants progress will be tracked for up to one year, or possibly two years, to understand both the success of the fusion and clinical outcomes. The total participation duration varies but includes regular follow-up visits within the first year after surgery.
CONDITIONS
Brief Title
OssiMend BA in Posterolateral Instrumented Lumbar Fusion
Research Team
M
Meenakshi Paliwal
P
Peggy Hansen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here